(Q37909430)

25 August 2017

1 reference

title

Using monoclonal antibodies to stimulate antitumor cellular immunity (English)

1 reference

25 August 2017

1 reference

1 reference

3

1 reference

25 August 2017

Lindy G Durrant

1

1 reference

25 August 2017

Victoria A Pudney

series ordinal

2

1 reference

25 August 2017

publication date

1 July 2011

1 reference

Expert Review of Vaccines

25 August 2017

published in

1 reference

25 August 2017

volume

10

1 reference

25 August 2017

issue

7

1 reference

25 August 2017

page(s)

1093-1106

1 reference

describes a project that uses

25 August 2017

1 reference

Mechanisms of killing by anti-CD20 monoclonal antibodies.

1 reference

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action

21 January 2018

1 reference

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

21 January 2018

1 reference

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

21 January 2018

1 reference

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.

21 January 2018

1 reference

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer

21 January 2018

1 reference

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic

21 January 2018

1 reference

From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice

21 January 2018

1 reference

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective

21 January 2018

1 reference

Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity

21 January 2018

1 reference

Fcgamma receptors: old friends and new family members

21 January 2018

1 reference

The role of the anaphylatoxins in health and disease

21 January 2018

1 reference

Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization

21 January 2018

1 reference

Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions

21 January 2018

1 reference

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

21 January 2018

1 reference

Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?

21 January 2018

1 reference

The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer

21 January 2018

1 reference

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

21 January 2018

1 reference

21 January 2018

DC-based cancer vaccines

1 reference

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells

21 January 2018

1 reference

Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells

21 January 2018

1 reference

Immune complex-mediated antigen presentation induces tumor immunity

21 January 2018

1 reference

Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens

21 January 2018

1 reference

Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance

21 January 2018

1 reference

Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.

21 January 2018

1 reference

Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma

21 January 2018

1 reference

Monoclonal antibodies for cancer immunotherapy

21 January 2018

1 reference

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

21 January 2018

1 reference

Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

21 January 2018

1 reference

Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma

21 January 2018

1 reference

Immunogenicity of an engineered internal image antibody

21 January 2018

1 reference

Efficient loading of identical viral peptide onto class II molecules by antigenized immunoglobulin and influenza virus

21 January 2018

1 reference

Priming of cytotoxic T lymphocytes at various stages of ontogeny with transfectoma cells expressing a chimeric Ig heavy chain gene bearing an influenza virus nucleoprotein peptide

21 January 2018

1 reference

Immunologic control of tumors by in vivo Fc gamma receptor-targeted antigen loading in conjunction with double-stranded RNA-mediated immune modulation

21 January 2018

1 reference

Antibodies designed as effective cancer vaccines.

21 January 2018

1 reference

Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases

21 January 2018

1 reference

In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells

21 January 2018

1 reference

Electroporation enhances immune responses and protection induced by a bovine viral diarrhea virus DNA vaccine in newborn calves with maternal antibodies

21 January 2018

1 reference

Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates

21 January 2018

1 reference

Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo

21 January 2018

1 reference

Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice

21 January 2018

1 reference

The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells

21 January 2018

1 reference

Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.

21 January 2018

1 reference

Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules

21 January 2018

1 reference

Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists

21 January 2018

1 reference

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics

21 January 2018

1 reference

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

21 January 2018

1 reference

The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology

21 January 2018

1 reference

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

21 January 2018

1 reference

CTLA-4-Ig regulates tryptophan catabolism in vivo.

21 January 2018

1 reference

Cutting edge: CTLA-4--B7 interaction suppresses Th17 cell differentiation

21 January 2018

1 reference

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

21 January 2018

1 reference

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

21 January 2018

1 reference

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

21 January 2018

1 reference

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

21 January 2018

1 reference

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

21 January 2018

1 reference

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo

21 January 2018

1 reference

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

21 January 2018

1 reference

Absence of Programmed Death Receptor 1 Alters Thymic Development and Enhances Generation of CD4/CD8 Double-Negative TCR-Transgenic T Cells

21 January 2018

1 reference

PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues

21 January 2018

1 reference

The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice

21 January 2018

1 reference

Tissue expression of PD-L1 mediates peripheral T cell tolerance.

21 January 2018

1 reference

Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4.

21 January 2018

1 reference

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

21 January 2018

1 reference

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

21 January 2018

1 reference

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients

21 January 2018

1 reference

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.

21 January 2018

1 reference

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

21 January 2018

1 reference

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli.

21 January 2018

1 reference

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

21 January 2018

1 reference

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

21 January 2018

1 reference

The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement

21 January 2018

1 reference

Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4.

21 January 2018

1 reference

Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist

21 January 2018

1 reference

Molecular and biological characterization of human 4-1BB and its ligand

21 January 2018

1 reference

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses

21 January 2018

1 reference

4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner

21 January 2018

1 reference

Phase I/II trial of tremelimumab in patients with metastatic melanoma

21 January 2018

1 reference

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

21 January 2018

1 reference

Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.11.33

1 reference

25 August 2017

1 reference